Clinical trials: Optic Nerve Pathology
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4)…
- Trial name
- NCT01892345
- Testing
- Eculizumab
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 143 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Supranuclear Palsy, Progressive
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
The purpose of this study is to evaluate the long-term safety and tolerability of multiple intravenous (IV) infusions of BIIB092 in participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT02658916
- Testing
- BIIB092
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- Biogen
Advanced Solid Tumor, Uveal Melanoma, Metastatic
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours.
- Conditions
- Advanced Solid Tumor, Uveal Melanoma, Metastatic, Cutaneous Melanoma
- Trial name
- NCT04855435
- Testing
- MBS8(1V270), MBS8(1V270) and pembrolizumab combination
- Where
- 5 sites in Denmark, Spain
- Volunteers
- 106 people
- Sponsor
- MonTa Biosciences ApS
Uveal Melanoma, Metastatic
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
The primary aim of the study is to establish the maximum-tolerated dose (MTD) of 225Ac-MTI-201 in participants with metastatic uveal melanoma.
- Trial name
- NCT05496686
- Testing
- 4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Modulation Therapeutics, Inc.
Refractory Cancer, Recurrent Cancer
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
- Trial name
- ACTengine (NCT03686124)
- Testing
- IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product
- Where
- 21 sites in United States, Germany
- Volunteers
- 375 people
- Sponsor
- Immatics US, Inc.
Progressive Supranuclear Palsy
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.
- Trial name
- NCT04993768
- Testing
- TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- Transposon Therapeutics, Inc.
Progressive Supranuclear Palsy, Corticobasal Syndrome
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome
- Trial name
- ROCKIT-1 (NCT04734379)
- Testing
- Fasudil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Woolsey Pharmaceuticals
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Progressive Supranuclear Palsy
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
- Trial name
- Tauros (NCT01049399)
- Testing
- tideglusib
- Where
- 24 sites in United States, Germany and 2 more
- Volunteers
- 146 people
- Sponsor
- Noscira SA
Leber Congenital Amaurosis 10, Blindness
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
- Trial name
- HYPERION (NCT06891443)
- Testing
- sepofarsen
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 32 people
- Sponsor
- Laboratoires Thea
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
PolG, Primary Mitochondrial Myopathy
Mitochondrial Video Assessment Source Material Study
Source material collection of videos to develop the Mitochondrial Video Assessment (MVA) for patients with mitochondrial myopathies.
- Trial name
- NCT06180421
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Emmes Company, LLC
Blepharospasm, Torticollis
MDs on Botox Utility (MOBILITY)
The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.
- Conditions
- Blepharospasm, Torticollis, Strabismus, Muscle Spasticity
- Trial name
- NCT00535938
- Testing
- botulinum toxin type A
- Where
- Canada
- Volunteers
- 1,372 people
- Sponsor
- Allergan
Progressive Supranuclear Palsy (PSP)
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
- Trial name
- NCT03413319
- Testing
- ABBV-8E12
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- AbbVie
Progressive Supranuclear Palsy, Corticobasal Degeneration
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
- Trial name
- NCT02167594
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C.
- Conditions
- Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome, Mitochondrial Myopathies
- Trial name
- NCT03888716
- Testing
- KL1333
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Abliva AB
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Ocular Motility Disorders, Strabismus
Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)
This prospective, multicenter, multinational observational study evaluates the clinical validity of an AI-based quantitative eye movement analysis system (Glandy EOM) that analyzes smartphone-recorded 9-gaze videos.
- Conditions
- Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
- Trial name
- GLANDY-EOM-VAL (NCT07623837)
- Testing
- Glandy EOM (AI-based quantitative eye movement analysis software)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- THYROSCOPE INC.